Last reviewed · How we verify
mFOLFIRINOX regimen
mFOLFIRINOX is a chemotherapy regimen combining 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
mFOLFIRINOX is a chemotherapy regimen combining 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Metastatic pancreatic cancer, Metastatic colorectal cancer, Gastric cancer.
At a glance
| Generic name | mFOLFIRINOX regimen |
|---|---|
| Also known as | modified FOLFIRINOX regimen, modified regimen of oxaliplatin, leucovorin, irinotecan, and fluorouracil (5-FU), Folic acid, 5- fluorouracil, irinotecan and oxaliplatin, Oxaliplatin, Irinotecan |
| Sponsor | Revolution Medicines, Inc. |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a combination chemotherapy regimen where each agent targets cancer cell proliferation through different mechanisms: 5-FU and leucovorin inhibit thymidylate synthase, irinotecan inhibits topoisomerase I, and oxaliplatin causes DNA cross-linking. The 'modified' (mFOLFIRINOX) version typically refers to adjusted dosing schedules designed to improve tolerability while maintaining efficacy compared to the standard regimen.
Approved indications
- Metastatic pancreatic cancer
- Metastatic colorectal cancer
- Gastric cancer
- Biliary tract cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Fatigue
- Peripheral neuropathy
- Anemia
- Thrombocytopenia
Key clinical trials
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) (PHASE1, PHASE2)
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (PHASE1, PHASE2)
- Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer (PHASE2)
- PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples (PHASE2)
- Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer (PHASE2)
- Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (PHASE2)
- A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |